QuickMD Review
Best for: Cost-conscious patients wanting same-day compounded or brand GLP-1 access
QuickMD is a high-volume telemedicine platform (over 1 million visits) offering same-day online weight-management care. It provides compounded semaglutide for about $279 per month and can prescribe brand-name GLP-1s including Wegovy, Zepbound, Ozempic, Mounjaro and oral Rybelsus, with medication costs varying by pharmacy. Visits are conducted entirely online by phone or video with licensed clinicians, available 365 days a year in 45-plus states. QuickMD uses transparent cash-pay pricing and does not bill insurance, though it provides visit summaries for possible reimbursement.
Medium confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
QuickMD is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
QuickMD prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide program | compounded | $279 |
✓ Pros
- •Compounded semaglutide around $279/mo plus brand-name GLP-1 options
- •Same-day, 365-day-a-year online visits
- •Large established platform with over 1 million completed visits
- •Transparent cash-pay pricing with reimbursement summaries
- •Can prescribe Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus
✗ Cons
- •Does not accept insurance
- •Available in 45+ states, not all 50
- •Medication cost varies by pharmacy, not fully bundled
- •No named board-certified physicians listed publicly
Ready to start with QuickMD?
Starting at $279/month. See current pricing and start your free consultation.
Sources & methodology
Our QuickMD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to QuickMD
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with QuickMD?
Starting at $279/month. See current pricing and start your free consultation.